MediWound (NASDAQ:MDWD) Rating Increased to Sell at StockNews.com

StockNews.com upgraded shares of MediWound (NASDAQ:MDWD) to a sell rating in a research note released on Friday morning.

Several other equities research analysts have also issued reports on MDWD. Craig Hallum assumed coverage on MediWound in a research note on Friday, February 28th. They set a “buy” rating and a $39.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of MediWound in a research note on Thursday.

MediWound Stock Down 4.6 %

Shares of MDWD stock opened at $16.27 on Friday. The business has a 50-day moving average price of $18.17 and a two-hundred day moving average price of $17.58. MediWound has a 12-month low of $12.78 and a 12-month high of $24.00. The firm has a market cap of $175.49 million, a P/E ratio of -5.61 and a beta of 0.82.

MediWound (NASDAQ:MDWD) last issued its quarterly earnings results on Wednesday, March 19th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.23. MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. The firm had revenue of $5.84 million during the quarter, compared to analyst estimates of $5.79 million. During the same quarter in the previous year, the company posted ($0.19) earnings per share. As a group, research analysts expect that MediWound will post -2.66 EPS for the current fiscal year.

Institutional Investors Weigh In On MediWound

Hedge funds and other institutional investors have recently modified their holdings of the stock. MetLife Investment Management LLC purchased a new position in MediWound during the 3rd quarter valued at about $89,000. Investor AB purchased a new position in MediWound during the 3rd quarter valued at about $15,750,000. Point72 Asset Management L.P. purchased a new position in MediWound during the 3rd quarter valued at about $212,000. State Street Corp increased its holdings in MediWound by 219.6% during the 3rd quarter. State Street Corp now owns 66,258 shares of the biopharmaceutical company’s stock valued at $1,197,000 after purchasing an additional 45,529 shares during the period. Finally, Barclays PLC increased its holdings in MediWound by 311.3% during the 3rd quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company’s stock valued at $202,000 after purchasing an additional 8,449 shares during the period. Institutional investors own 46.83% of the company’s stock.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.